Skip to main content

0157 A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473 in Subjects with Moderately-to-Severely Active Ul

NCT03758443

A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473 in Subjects with Moderately-to-Severely Active Ulcerative Colitis

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Theravance Biopharma

The purpose of this study is: (a) To select dose(s) of TD-1473 to move into further testing; (b) To evaluate the effectiveness of TD-1473 in treating subjects with moderately-to-severely active UC; (c) To assess the safety of TD-1473, how well tolerated it is, and how study treatment with TD-1473 affects quality of life; and (d) To measure the way the body absorbs, distributes, and gets rid of TD-1473 (known as pharmacokinetics) and to examine the effects of TD-1473 on the human body (known as pharmacodynamics).